HTRA1 and B-cell non-Hodgkin lymphoma: In a mouse subcutaneous H22 hepatocellular carcinoma model and a mouse subcutaneous A20 B‐cell lymphoma model, the tumor weight in the AISI‐pLuxI‐htrA‐treated group was 40.9% and 48.4% lower, respectively, on day 10 post‐treatment than that in the AISI‐NC‐treated group (Figure S10B,C,G,H, Supporting Information).